Caspian Journal of Internal Medicine
Babol University of Medical Sciences
شنبه 11 بهمن 1404
[Archive]
دوره 17، شماره 1 - ( 10-1404 )
جلد 17 شماره 1 صفحات 36-14 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Kharisma Dewi N N G, Yunia Dewi N L P, Lesmana Dewi P I S, Narapati Pamungkas K M, Sindhughosa D A, Mariadi I K. Efficacy and safety of potassium-competitive acid blockers in eradicating Helicobacter pylori and treating gastro-esophageal reflux disease: A systematic review and meta-analysis. Caspian J Intern Med 2026; 17 (1) :14-36
URL: http://caspjim.com/article-1-4436-fa.html
URL: http://caspjim.com/article-1-4436-fa.html
Efficacy and safety of potassium-competitive acid blockers in eradicating Helicobacter pylori and treating gastro-esophageal reflux disease: A systematic review and meta-analysis. . 1404; 17 (1) :14-36
چکیده: (635 مشاهده)
Background: This systematic review aimed to assess the efficacy and safety of PCAB versus PPI in eradicating H. pylori and GERD.
Methods: The studies were searched through databases of PubMed, ScienceDirect, Wiley Online Library, and CENTRAL. A random-effects meta-analysis was performed to evaluate the efficacy and safety of PCAB in eradicating H. pylori and treating GERD, using odds ratios (OR) and 95% confidence intervals (95%CI) as the effect measures.
Results: PCAB therapy demonstrated superior efficacy and safety compared to PPI-based therapy in eradicating H. pylori (efficacy OR 1.40 [95% CI 1.12–1.76]; safety OR 0.71 [0.52–0.95]) and treating GERD (efficacy OR 1.62 [1.01–2.61]; safety OR 0.90 [0.71–1.14]). Vonoprazan therapy, but not tegoprazan, particularly showed superiority, with ORs of 1.66 [1.24–2.23] for H. pylori eradication (safety OR 0.71 [0.52–0.95]) and 1.80 [1.00–3.25] for GERD (safety OR 1.03 [0.83–1.27]). For H. pylori eradication, vonoprazan triple therapy showed greater efficacy overall (OR 1.94 [1.19–3.17]) and compared to lansoprazole (OR 2.84 [1.97–4.11]) and rabeprazole (OR 2.63 [1.05–6.58]), though not compared to esomeprazole (OR 1.62 [0.69–3.81]). In GERD treatment, both short-term (8 weeks) and long-term (24 weeks) vonoprazan therapies were similarly effective (OR 2.55 [1.71–3.80] and OR 2.17 [1.00–4.72], respectively) and showed particular efficacy in patients with severe (grade C/D) reflux esophagitis (OR 3.51 [1.65–7.46]).
Conclusions: Vonoprazan had a superior efficacy than PPI in eradicating H. pylori and treating GERD, but not for tegoprazan. PCAB demonstrated a favorable safety profile.
Methods: The studies were searched through databases of PubMed, ScienceDirect, Wiley Online Library, and CENTRAL. A random-effects meta-analysis was performed to evaluate the efficacy and safety of PCAB in eradicating H. pylori and treating GERD, using odds ratios (OR) and 95% confidence intervals (95%CI) as the effect measures.
Results: PCAB therapy demonstrated superior efficacy and safety compared to PPI-based therapy in eradicating H. pylori (efficacy OR 1.40 [95% CI 1.12–1.76]; safety OR 0.71 [0.52–0.95]) and treating GERD (efficacy OR 1.62 [1.01–2.61]; safety OR 0.90 [0.71–1.14]). Vonoprazan therapy, but not tegoprazan, particularly showed superiority, with ORs of 1.66 [1.24–2.23] for H. pylori eradication (safety OR 0.71 [0.52–0.95]) and 1.80 [1.00–3.25] for GERD (safety OR 1.03 [0.83–1.27]). For H. pylori eradication, vonoprazan triple therapy showed greater efficacy overall (OR 1.94 [1.19–3.17]) and compared to lansoprazole (OR 2.84 [1.97–4.11]) and rabeprazole (OR 2.63 [1.05–6.58]), though not compared to esomeprazole (OR 1.62 [0.69–3.81]). In GERD treatment, both short-term (8 weeks) and long-term (24 weeks) vonoprazan therapies were similarly effective (OR 2.55 [1.71–3.80] and OR 2.17 [1.00–4.72], respectively) and showed particular efficacy in patients with severe (grade C/D) reflux esophagitis (OR 3.51 [1.65–7.46]).
Conclusions: Vonoprazan had a superior efficacy than PPI in eradicating H. pylori and treating GERD, but not for tegoprazan. PCAB demonstrated a favorable safety profile.
نوع مطالعه: Original Article |
موضوع مقاله:
Gastroentrology
دریافت: 1403/4/20 | پذیرش: 1403/10/2 | انتشار: 1404/10/21
دریافت: 1403/4/20 | پذیرش: 1403/10/2 | انتشار: 1404/10/21
Supplementary [PDF 959 KB] (6 دریافت)
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
